Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review.

BMC medical genomics - 14 Mar 2025

Wang Kang-Xin, Yang Xu-Dong, Guo Fen, Sun Hui, Fang Yue-Yu, Jiang Nan-Yuan, Chen Xiao-Feng

Abstract excerpt

BACKGROUND: Some genetically characterized patients show the rapid disease progression during immune checkpoint inhibitors (ICIs) monotherapy, a phenomenon known as hyperprogressive disease (HPD). CASE PRESENTATION: Herein we report a relevant case of biliary tract cancer (BTC) that initially responded to gemcitabine plus oxaliplatin (GEMOX) and PD-1 blockade but subsequently developed HPD in the process of PD-1...

Read the complete abstract on PubMed

Topics

Humans
Biliary Tract Neoplasms
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor
Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Mutation

Disease Progression

Middle Aged

Female

Source

Open in PubMed Open full text

Identifiers

PMID: 40087618
DOI: 10.1186/s12920-025-02097-5
PMCID: PMC11909846

Genes

HPD
KRAS
BTC
CDKN2A
EPHA2
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review.PMID 40087618Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

Molecular profiling of biliary tract cancer: a target rich diseaseSemantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

[Progress of genomic mutation spectrum in biliary tract malignant tumors].Semantic proximity Read ↗

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug TargetsSemantic proximity Read ↗

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Translating cancer genomics for precision oncology in biliary tract cancers.Semantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

Genetics of Biliary Tract Cancers and Emerging Targeted TherapiesSemantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment OptionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.